Appointments Jobs About Search Education & Research Clinical Trials Health Information Medical Services

Publications - Ruben A . Mesa, M.D.

Back to Research Profile

  1. Goldman JM, Green AR, Holyoake T, Jamieson C, Mesa R, Mughal T, Pellicano F, Perrotti D, Skoda R, Vannucchi AM. Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia 2009 Oct; 23(10):1708-15.
    View PubMed
  2. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009 Sep 20; 27(27):4563-9. Epub 2009 Aug 03.
    View PubMed
  3. Mesa R, Gale RP. Hypothesis: how do JAK2-inhibitors work in myelofibrosis. Leuk Res 2009 Sep; 33(9):1156-7. Epub 2009 May 17.
    View PubMed
  4. Mesa RA, Tefferi A. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs 2009 Sep; 14(3):471-9.
    View PubMed
  5. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009 Sep; 33(9):1199-203. Epub 2009 Feb 27.
    View PubMed
  6. Mesa RA, Tefferi A. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs 2009 Sep; 14(3):471-9.
    View PubMed
  7. Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 2009 May 28; 113(22):5394-400. Epub 2009 Mar 30.
    View PubMed
  8. Tefferi A, Mesa RA, Pardanani A, Hussein K, Schwager S, Hanson CA, Steensma DP. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol 2009 May; 84(5):265-7.
    View PubMed
  9. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009 May; 23(5):905-11. Epub 2009 Mar 05.
    View PubMed
  10. Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson CM, Ketterling RP, Hanson CA, Van Dyke DL, Tefferi A. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol 2009 Apr; 82(4):255-9. Epub 2008 Feb 10.
    View PubMed
  11. Mesa RA. How I Treat Symptomatic Splenomegaly in Myelofibrosis Patients Blood 2009.
    View PubMed
  12. Mesa RA. New drugs for the therapy of myelofibrosis. Current Hematologic Malignancy Reports 2009; 5(1).
    View PubMed
  13. Hussein K, Ketterling RP, Dewald GW, Van Dyke DL, Mesa R, Hanson CA, Tefferi A. Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studies. Leuk Res 2008 Oct; 32(10):1597-600. Epub 2008 Feb 01.
    View PubMed
  14. Mott JL, Bronk SF, Mesa RA, Kaufmann SH, Gores GJ. BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol Cancer Ther 2008 Aug; 7(8):2339-47.
    View PubMed
  15. Mesa RA, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T, Wu W, Tefferi A. Bortezomib therapy in myelofibrosis: a phase II clinical trial. Leukemia 2008 Aug; 22(8):1636-8 Epub 2008 Feb 28.
    View PubMed
  16. Huang J, Li CY, Mesa RA, Wu W, Hanson CA, Pardanani A, Tefferi A. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008 Jun 15; 112(12):2726-32.
    View PubMed
  17. Mesa RA, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T, Wu W, Tefferi A. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 2008 May 29. [Epub ahead of print]
    View PubMed
  18. Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi A. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 2008 May; 83(5):363-5.
    View PubMed
  19. Steensma DP, Heptinstall KV, Johnson VM, Novotny PJ, Sloan JA, Camoriano JK, Niblack J, Bennett JM, Mesa RA. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res 2008 May; 32(5):691-8. Epub 2007 Dec 04.
    View PubMed
  20. Tefferi A, Gangat N, Wolanskyj AP, Schwager S, Pardanani A, Lasho TL, Mesa R, McClure RF, Li CY, Hanson CA. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. Eur J Haematol 2008 May; 80(5):386-90. Epub 2008 Jan 23.
    View PubMed
  21. Mesa R. Myeloproliferative disorder-associated massive splenomegaly. Clin Adv Hematol Oncol 2008 Apr; 6(4):278, 281-2.
    View PubMed
  22. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, Wu W, Hanson CA, Pardanani A. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008 Apr; 22(4):756-61. Epub 2008 Jan 24.
    View PubMed
  23. Kroger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 2008 Mar; 22(3):474-86. Epub 2008 Jan 10.
    View PubMed
  24. Mesa RA. New insights into the pathogenesis and treatment of chronic myeloproliferative disorders. Curr Opin Hematol 2008 Mar; 15(2):121-6.
    View PubMed
  25. Knoll B, Rea DJ, Szoztek J, Nagorney DS, Tefferi A, Mesa RA. Extramedullary hematopoiesis. Am J Hematol 2008 Feb; 83(2):171.
    View PubMed
  26. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A, International Working Group for Myelofibrosis Research and Treatment (IW Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008 Feb; 22(2):437-8 Epub 2007 Aug 30.
    View PubMed
  27. Mesa RA. Imatinib Mesylate for the BCR-ABL Negative Myeloproliferative Disorders. Biologics: Targets and Therapy 2008.
    View PubMed
  28. Mesa RA. Blastic Transformation in Myeloproliferative Disorders Haematologica 2008; 2(Suppl1):216-223.
    View PubMed
  29. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi A, Mesa RA, Demory J-L, Barosi G, Rumi E, Tefferi A. A New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research, Treatment. Blood 2008. [Epub ahead of print]
    View PubMed
  30. Hussein K, Ketterling R, Dewald G, VanDyke D, Mesa R, Hanson C, Tefferi A. Peripheral blood cytogenetic studies in myelofibrosis: Overall yield and comparison with bone marrow cytogenetic studies. Journal of Leukemia Research 2007 Dec; 10:1016.
    View PubMed
  31. Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J 2007 Nov-Dec; 13(6):377-83.
    View PubMed
  32. Elliott MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 2007 Nov; 31(11):1503-9. Epub 2007 Mar 29.
    View PubMed
  33. Pardanani A, Lasho TL, Finke C, Mesa RA, Hogan WJ, Ketterling RP, Gilliland DG, Tefferi A. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells 2007 Sep; 25(9):2358-62. Epub 2007 May 31.
    View PubMed
  34. Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, Erlichman C, Wright J, Pardanani A, Lasho T, Finke C, Li CY, Tefferi A. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia 2007 Sep; 21(9):1964-70. Epub 2007 Jun 21.
    View PubMed
  35. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007 Aug 15; 110(4):1092-7. Epub 2007 May 08.
    View PubMed
  36. Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 2007 Aug; 21(8):1827-8. Epub 2007 Apr 26.
    View PubMed
  37. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007 Aug; 21(8):1658-68. Epub 2007 May 31.
    View PubMed
  38. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, Levine R, Le Bousse-Kerdiles MC, Wadleigh M, Campbell PJ, Silver RT, Vannucchi AM, Deeg HJ, Gisslinger H, Thomas D, Odenike O, Solberg LA, Gotlib J, Hexner E, Nimer SD, Kantarjian H, Oraz Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research Leuk Res 2007 Jun; 31(6):737-40. Epub 2007 Jan 08.
    View PubMed
  39. Mesa RA. Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders. Biologics 2007 Jun; 1(2):129-38.
    View PubMed
  40. Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A, Mesa RA. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer 2007 May 15; 109(10):2083-8.
    View PubMed
  41. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) - an international internet-based survey of 1179 MPD patients. Cancer 2007 Jan 1; 109(1):68-76.
    View PubMed
  42. Mesa RA. Management of MPDs: Update on the Latest Development on Diagnosis and Treatment Korean Journal of Hematology 2007; 42 (Suppl 2):2-4.
    View PubMed
  43. Mesa RA. Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2007; 355-62.
    View PubMed
  44. Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gilliland DG, Tefferi A. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 2006 Dec; 135(5):683-7.
    View PubMed
  45. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006 Nov 15; 108(10):3472-6. Epub 2006 Jul 25.
    View PubMed
  46. Mesa RA, Powell H, Lasho T, Dewald G, McClure R, Tefferi A. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk Res 2006 Nov; 30(11):1457-60. Epub 2006 Mar 23.
    View PubMed
  47. Mesa RA, Tefferi A, Lasho TS, Loegering D, McClure RF, Powell HL, Dai NT, Steensma DP, Kaufmann SH. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Leukemia 2006 Oct; 20(10):1800-8. Epub 2006 Jul 27.
    View PubMed
  48. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NCP, Gilliland DG, Kantarjian H. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006 Sep 1; 108(5):1497-503.
    View PubMed
  49. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA Jr, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H, International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006 Sep 1; 108(5):1497-503. Epub 2006 May 04.
    View PubMed
  50. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006 Aug 15; 108(4):1158-64. Epub 2006 Apr 11.
    View PubMed
  51. Mesa RA. Practical management of classical myeloproliferative disorder patients: a clinician's guide. Future Oncol 2006 Aug; 2(4):515-24.
    View PubMed
  52. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006 Jul 15; 107(2):361-70.
    View PubMed
  53. Gangat N, Wolanskyj AP, Schwager SM, Mesa RA, Tefferi A. Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia. Cancer 2006 Jun 1; 106(11):2406-11.
    View PubMed
  54. Tefferi A, Dingli D, Li CY, Mesa RA. Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates. Leuk Res 2006 Jun; 30(6):677-80. Epub 2005 Nov 08.
    View PubMed
  55. Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer 2006 May 1; 106(9):1985-9.
    View PubMed
  56. Tefferi A, Strand JJ, Lasho TL, Elliott MA, Li CY, Mesa RA, Dewald GW. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy. Cancer 2006 Apr 15; 106(8):1739-43.
    View PubMed
  57. Mesa RA. Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert Rev Anticancer Ther 2006 Mar; 6(3):313-9.
    View PubMed
  58. Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer 2006 Feb 1; 106(3):623-30.
    View PubMed
  59. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Li CY, Wadleigh M, Lee SJ, Gilliland DG. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006 Feb 1; 106(3):631-5.
    View PubMed
  60. Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, Tefferi A, Elliot MA, Kaufmann SH, Mesa RA, Litzow MR. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006 Jan; 20(1):29-34.
    View PubMed
  61. Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, Tefferi A, Elliott MA, Kaufmann SH, Mesa RA, Litzow MR. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006 Jan; 20(1):29-34.
    View PubMed
  62. Mesa RA, Barosi G, Cervantes F, Reilly JT, Tefferi A. Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options. Best Pract Res Clin Haematol 2006; 19(3):495-517.
    View PubMed
  63. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gilliland DG. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. British Journal of Haematology 2005 Nov; 131(3):320-8.
    View PubMed
  64. Mesa R. Pegylated Interferon for the treatment of high-risk essential thrombocythemia. Haematologica 2005 Oct; 90(10):1298.
    View PubMed
  65. Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, Wolanskyj AP, Steensma DP, Mesa R, Gilliland DG. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 2005 Oct; 131(2):166-71.
    View PubMed
  66. Mesa RA, Tefferi A. Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia. Semin Oncol 2005 Aug; 32(4):403-13.
    View PubMed
  67. Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SJ, Dai NT, Heldebrant MP, Vroman BT, Smith BD, Karp JE, Eyck CJ, Erlichman C, Kaufmann SH, Karnitz LM. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 2005 Jul 1; 106(1):318-27.
    View PubMed
  68. Goel A, Dispenzieri A, Greipp PR, Witzig TE, Mesa RA, Russell SJ. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp Hematol 2005 Jul; 33(7):784-95.
    View PubMed
  69. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, Boggon TJ, Wlodarska L, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005 Apr; 7(4):387-97.
    View PubMed
  70. Mesa RA, Li CY, Kettering RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005 Feb 1; 105(3):973-7.
    View PubMed
  71. Faoro LN, Tefferi A, Mesa RA. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol 2005 Feb; 74(2):117-20.
    View PubMed
  72. Arora B, Sirhan S, Hoyer JD, Mesa RA, Tefferi A. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol 2005 Jan; 128(1):42-8.
    View PubMed
  73. Ho CL, Arora B, Hoyer JD, Wellik LE, Mesa RA, Tefferi A. Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia. Eur J Haematol 2005 Jan; 74(1):35-9.
    View PubMed
  74. Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol 2005 Jan; 74(1):47-53.
    View PubMed
  75. Arora B, Mesa RA, Tefferi A. Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia. Leuk Lymphoma2004 Dec; 45(12):2373-86.
    View PubMed
  76. Arora B, Ho CL, Hoyer JD, Mesa RA, Tefferi A. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia. Haematologica 2004 Dec; 89(12):1454-8.
    View PubMed
  77. Elliott MA, Wolf RC, Hook CC, Pruthi RK, Heit JA, Letendre LL, Tefferi A, Kaufmann SH, Mesa RA, Litzow MR. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: Incidence, risk factors, and possible role of antithrombin. Leukemia & Lymphoma 2004 Aug; 45(8):1545-9.
    View PubMed
  78. Dingli D, Mesa RA, Tefferi A. Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment. Intern Med 2004 Jul; 43(7):540-7.
    View PubMed
  79. Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc 2004 Jul; 79(7):883-9.
    View PubMed
  80. Tefferi A, Lasho TL, Wolanskyj AP, Mesa RA. Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood 2004 May 1; 103(9):3547-8.
    View PubMed
  81. Koch CA, Li CY, Mesa RA, Tefferi A. Nonhepatosplenic extramedullary hematopoiesis: Associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc 2003 Oct; 78(10):1223-33.
    View PubMed
  82. Lindor NM, Dozois R, Nelson H, Wolff B, King J, Boardman L, Wilson M, Greene MH, Karnes W, Mesa R, Welch T, Edmonson J, Limburg P. Desmoid tumors in familial adenomatous polyposis: A pilot project evaluating efficacy of treatment with pirfenidone. Am J Gastroenterol 2003 Aug; 98(8):1868-74.
    View PubMed
  83. Mesa RA, Tefferi A, Gray LA, Reeder T, Schroeder G, Kaufmann SH. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia 2003 May; 17(5):849-55.
    View PubMed
  84. Mesa RA. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003. Current Hematology Reports 2003 May; 2(3):264-70.
    View PubMed
  85. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder GE, Reeder T, Zeldis JB, Tefferi A. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003 Apr 1; 101(7):2534-41.
    View PubMed
  86. Mesa RA. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders. Int J Hematol 2002 Aug; 76(Suppl 2):193-203.
    View PubMed
  87. Mesa RA. The therapy of myelofibrosis: Targeting pathogenesis. Int J Hematol 2002 Aug; 76(Suppl 2):296-304.
    View PubMed
  88. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002 Jul; 8(7):2210-6.
    View PubMed
  89. Mesa RA, Hanson CA, Li CY, Yoon SY, Rajkumar SV, Schroeder G, Tefferi A. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood 2002 Jun 1; 99(11):4131-7.
    View PubMed
  90. Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA, Pardanani A, Ansell SM, Call TG, Colon-Otero G, Schroeder G, Hanson CA, Dewald GW, Kaufmann SH. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood 2002 May 15; 99(10):3854-6.
    View PubMed
  91. Elliott MA, Mesa RA, Li CY, Hook CC, Ansell SM, Levitt RM, Geyer SM, Tefferi A. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002 May; 117(2):288-96.
    View PubMed
  92. Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood 2002 Mar 15; 99(6):2252-4.
    View PubMed
  93. Elliott MA, Mesa RA, Tefferi A. Adverse events after imatinib mesylate therapy. N Engl J Med 2002 Feb 28; 346(9):712-3.
    View PubMed
  94. Rajkumar SV, Mesa RA, Tefferi A. A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies. J Hematother Stem Cell Res 2002 Feb; 11(1):33-47.
    View PubMed
  95. Mesa RA. The Therapy of Myelofibrosis with Myeloid Metaplasia. International Journal of Hematology 2002; 76:296-304.
    View PubMed
  96. Mesa RA. The Therapy of Myelofibrosis with Myeloid Metaplasia. International Journal of Hematology 2002; 76:296-304.
    View PubMed
  97. Mesa RA. Clinical Advances in the Philadelphia-Chromosome Negative Chronic Myeloproliferative Disorders International Journal of Hematology 2002; 76:193-203.
    View PubMed
  98. Mesa RA, Tefferi A. Palliative splenectomy in myelofibrosis with myeloid metaplasia. Leuk Lymphoma 2001 Sep-Oct; 42(5):901-911.
    View PubMed
  99. Mesa RA, Tefferi A, Elliott MA, Hoagland HC, Call TG, Schroeder GS, Yoon SY, Li CY, Gray LA, Margolin S, Hook CC. A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Haematol 2001 Jul; 114(1):111-3.
    View PubMed
  100. Mesa RA, Li CY, Schroeder G, Tefferi A. Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood 2001 Jun 1; 97(11):3665-7.
    View PubMed
  101. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001 Jun; 113(3):763-71.
    View PubMed
  102. Tefferi A, Jimenez T, Gray LA, Mesa RA, Chen MG. Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. Eur J Haematol 2001 Jan; 66(1):37-42.
    View PubMed
  103. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000 Nov 15; 96(10):3374-80.
    View PubMed
  104. Mesa RA, Elliott MA, Tefferi A. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia. Blood Rev 2000 Sep; 14(3):121-9.
    View PubMed
  105. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000 Apr 1; 95(7):2226-33.
    View PubMed
  106. Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1999 Sep; 106(3):682-8.
    View PubMed
  107. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 1999 May; 61(1):10-5.
    View PubMed
  108. Mesa RA, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 1998 Jan; 73(1):37-45.
    View PubMed
  109. Tefferi A, Bartholmai BJ, Witzig TE, Jenkins RB, Li CY, Hanson CA, Mesa RA, Phyliky RL. Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia. Cancer Genetics & Cytogenetics 1997 Jun; 95(2):173-7.
    View PubMed
  110. Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, and current indications. Semin Thromb Hemost 1997; 23(4):379-83.
    View PubMed


Appointments Contact Us Make A Gift Search

Legal restrictions and terms of use applicable to this site

Use of this site signifies your agreement to the terms of use
Copyright © 2009 Mayo Foundation for Medical Education and Research.